Prof. Dr. med. Stefan Fröhling
Acting Managing Director, National Center for Tumor Diseases (NCT) Heidelberg
Head, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ)
Since April 2018, Professor Stefan Fröhling has been Acting Managing Director of NCT Heidelberg. In addition, he heads the division of Translational Medical Oncology at NCT/DKFZ. Stefan Fröhling’s research aims at providing as many patients as possible with individually tailored cancer treatments.
As part of the Precision Oncology Program, much of his work is centered on the development of tools for the comprehensive molecular and functional characterization of individual tumors, and the conception of clinical studies examining the efficacy of modern, molecularly targeted treatment approaches. In addition to his research in the precision oncology field, Stefan Fröhling particularly focuses on the biology of bone and soft-tissue sarcomas as well as acute forms of leukemia.
Research Field
Cancer Genomics, Precision Oncology, Molecular Pathogenesis and Therapeutic Targeting of Acute Myeloid Leukemia and Bone and Soft-Tissue Sarcoma
Selected Activities in the Scientific Community
Principal Investigator, MASTER Program of the German Cancer Consortium (DKTK) | Coordinator, DKTK Research Platform Cancer Genome and Proteome Analysis | Elected Member, Board of the European Hematology Association | Editor, Blood, Journal of the American Society of Hematology | Associate Editor, HemaSphere, Journal of the European Hematology Association | Editor, Cold Spring Harbor Molecular Case Studies | Member, Cancer Core Europe Board of Directors
